| Presenilin Enhancer 2 (PEN-2) | |
|---|---|
| Gene | PSENEN |
| UniProt | Q9NQ75 |
| PDB | 5A63, 6IDF |
| Mol. Weight | ~10 kDa (101 aa, two transmembrane domains) |
| Localization | Endoplasmic reticulum, Golgi apparatus, plasma membrane |
| Family | PEN-2 family (γ-secretase complex) |
| Diseases | Alzheimer's Disease, Frontotemporal Dementia |
Presenilin Enhancer 2 (Pen 2) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Presenilin Enhancer 2 (PEN-2) is the smallest and final subunit to join the γ-secretase complex, which also includes presenilin (PSEN1/PSEN2), nicastrin (NCT), and APH-1[1]. Despite its small size, PEN-2 is essential for γ-secretase activity - it serves as the enzymatic component that directly contributes to the aspartyl protease activity of the complex. PEN-2 was originally identified in a genetic screen in C. elegans as an enhancer of presenilin mutants, giving it its name[2].
PEN-2 is a unique membrane protein with only two transmembrane domains, forming a hairpin structure that inserts into the membrane. It is required for the endoproteolysis of presenilin and for the stabilization of the active γ-secretase complex[3].
PEN-2 is a 101-amino acid protein with a distinctive hairpin topology:
PEN-2 plays multiple critical roles:
The γ-secretase complex processes numerous type I transmembrane proteins:
PEN-2 directly affects amyloid-β production:
Understanding PEN-2's role has informed drug development:
γ-secretase and thus PEN-2:
The sequential assembly of γ-secretase follows a specific order:
PEN-2 is the final subunit added and is essential for converting the precursor complex into an active enzyme.
The study of Presenilin Enhancer 2 (Pen 2) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Steiner H, Fluhrer R, Haass C. Gamma-secretase: a multidisciplinary target for the treatment of Alzheimer's disease. J Biol Chem. 2008;283(44):29633-29637. DOI:10.1074/jbc.R800010200 ↩︎
Edbauer D, Winkler E, Regula JT, et al. Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5(5):486-488. DOI:10.1038/ncb983 ↩︎
Prokop S, Haass C, Steiner H. Structure and function of γ-secretase. Nat Rev Neurosci. 2005;6(9):675-688. DOI:10.1038/nrn1733 ↩︎